



Improving the computation efficiency of polygenic risk score modeling: faster in Julia

Annika Faucon^{1,*}, Julian Samaroo^{2,*}, Tian Ge³, Lea K Davis^{1,4} , Nancy J Cox^{1,4} , Ran Tao^{1,5}, Megan M Shuey^{1,4} 

To enable large-scale application of polygenic risk scores (PRSs) in a computationally efficient manner, we translate a widely used PRS construction method, PRS-continuous shrinkage, to the Julia programming language, PRS.jl. On nine different traits with varying genetic architectures, we demonstrate that PRS.jl maintains accuracy of prediction while decreasing the average runtime by 5.5×. Additional programmatic modifications improve usability and robustness. This freely available software substantially improves work flow and democratizes usage of PRSs by lowering the computational burden of the PRS-continuous shrinkage method.

DOI [10.26508/lsa.202201382](https://doi.org/10.26508/lsa.202201382) | Received 21 January 2022 | Revised 5 July 2022 | Accepted 6 July 2022 | Published online 18 July 2022

Introduction

The conceptual framework known as the “liability-threshold model” asserts that complex diseases have many contributing variants of small effect, which collectively contribute to a continuous distribution of genetic liability in a population. Thus, when a large-enough collection of risk alleles is aggregated in an individual together with environmental risk factors such that they pass a critical threshold, the complex disease will manifest (Falconer, 1965). The additive genetic portion of this liability attributable to common variants can be estimated with a polygenic risk score (PRS). A PRS is generally calculated as a weighted sum of risk alleles present in an individual genome, where the weights are defined by the effects estimated in genome-wide association studies (GWASs) (Chatterjee et al, 2016).

Since the advent of PRS methods, various studies have proven their potential to improve health by informing therapeutic intervention (Tikkanen et al, 2013; Mega et al, 2015), disease screening (Hsu et al, 2015), and lifestyle choices for a multitude of polygenic conditions. In fact, polygenic risk scoring has long been at the center of genetic research (MultiBLUP [Speed & Balding, 2014], PLINK [Purcell et al, 2007], PRSice [Choi & O’Reilly, 2019], LDpred

[Vilhjalmsson et al, 2015]). In simulation and real data analyses, PRS-continuous shrinkage (CS) was demonstrated as a top-performing method (Ge et al, 2019; Pain et al, 2021). Despite their popularity and importance, PRS methods need development, particularly related to computational expense. As large datasets become publicly available and computation moves to the cloud (Langmead & Nellore, 2018), research demands the use of computational programs that can scale and cost-effectively use resources. Because the Julia programming language has consistently demonstrated increased efficiency of computation over other programming languages, along with other advantages (Bezanson et al, 2018), we created a Julia translation of the commonly used Python based PRS-CS program, PRS.jl.

Below, we introduce the PRS.jl program and benchmark it against PRS-CS, tracking model accuracy and computational improvements across nine well-characterized polygenic phenotypes including both continuous and binary outcomes.

Results

PRS.jl performance overview

PRS.jl is a direct translation of the PRS-CS Python program into the Julia language. This translation improves the computational efficiency of PRS estimation across a variety of polygenic traits.

Using the auto global shrinkage calculation with 10,000 MCMC iterations on a single Haswell node, eight CPUs available total, and a maximum memory allocation of 80 GB, we observed an average 5.5× improvement in computational speeds when using PRS.jl compared with PRS-CS across nine phenotypes. The improvements in speed ranged from 3.8× to 6.4× (Table 1). For the quantitative phenotypes – body mass index, high-density lipid cholesterol, low-density lipid cholesterol, total cholesterol, triglycerides, and estimated glomerular filtration rate – the average improvement was 5.6×. For the binary traits – asthma, coronary artery disease, and type 2 diabetes mellitus – the improvement was 5.1×. These

¹Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA ²JuliaLab, Massachusetts Institute of Technology, Boston, MA, USA ³Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA ⁴Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA ⁵Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

Correspondence: megan.m.shuey.1@vumc.org

*Annika Faucon and Julian Samaroo contributed equally to this work.

Table 1. Individual and average runtimes for polygenic risk score–continuous shrinkage (PRS-CS) and PRS.jl by phenotype.

	PRS-CS				PRS.jl				Average
	Run 1	Run 2	Run 3	Mean (SD)	Run 1	Run 2	Run 3	Mean (SD)	Improvement ^a
Quantitative phenotypes									
Body mass index	62:21:25	65:12:16	59:41:13	62:24:58 (1:28:32)	12:01:15	12:20:31	11:19:32	11:53:46 (0:31:10)	5.3
Cholesterol	56:51:43	55:36:35	59:12:59	57:13:46 (1:49:52)	12:07:50	8:15:23	12:34:38	10:59:17 (2:22:34)	5.2
eGFR	65:52:20	69:43:40	77:57:50	71:11:17 (6:10:36)	13:54:28	15:57:40	14:01:35	14:37:54 (1:09:10)	4.9
High-density lipoprotein	59:58:13	56:39:56	59:19:08	58:39:06 (1:45:02)	8:21:45	8:16:13	10:58:48	9:12:15 (1:32:19)	6.4
Low-density lipoprotein	63:38:06	56:17:24	56:47:47	58:54:26 (4:06:08)	8:26:04	8:18:47	12:54:02	9:52:58 (2:36:51)	6.0
Triglycerides	58:00:52	56:04:48	60:45:49	58:17:10 (2:21:13)	8:18:01	8:09:24	11:48:25	9:25:17 (2:04:02)	6.2
Binary phenotypes									
Asthma	41:58:26	40:15:14	41:29:02	41:14:14 (0:53:10)	5:26:44	6:25:06	7:27:54	6:26:35 (1:00:36)	6.4
Coronary artery disease	66:59:45	66:00:16	64:05:35	65:41:52 (1:28:32)	10:43:53	15:05:15	13:04:09	12:57:46 (2:10:48)	5.1
Type 2 diabetes mellitus	68:35:38	69:10:26	68:08:43	68:38:16 (0:30:57)	17:03:18	20:13:24	16:38:33	17:58:25 (1:57:33)	3.8
All phenotypes combined									
	544:16:28	535:00:35	547:28:06	542:15:03 (6:28:16)	96:23:18	103:01:43	110:47:36	103:24:12 (7:12:35)	5.5

All runtimes are presented as hour:minutes:seconds.

^aAverage improvement is estimated as the mean PRS-CS/mean PRS.jl.

reported computational times represent the total amount of runtime when chromosomes are sequentially analyzed; processing the chromosomes in parallel can substantially reduce time to results.

We next demonstrate that these improvements in speed did not come at the expense of PRS accuracy (Fig 1).

Next, we show the retained accuracy of PRS.jl estimate for given phenotypes by demonstrating the consistency of posterior SNP weights and the resulting PRSs compared with PRS-CS. Specifically, to assess the consistency of SNP weights, we calculate the squared error for each SNP between the PRS.jl and PRS-CS output (Table 2). The median squared error between the two algorithms ranged from 2.00×10^{-11} to 6.83×10^{-11} across phenotypes, with a median of 3.00×10^{-11} . This is similar to the median squared errors within the same program on different runs (Table S1). A *t* test comparing the posterior SNP effect sizes estimated by PRS.jl and PRS-CS found no statistically significant difference (all *P* > 0.85).

We examined accuracy of the PRSs relative to the traits measured in BioVU. For the quantitative traits, we compared prediction accuracy by R^2 between the observed and predicted phenotypes in the BioVU testing set (Table 3). For the binary traits, we compared prediction accuracy by area under the curve (AUC), the Nagelkerke R^2 , and the odds ratio of the top 10% versus the remaining 90% (Table 4). PRS-CS and PRS.jl had nearly identical accuracies across all tested traits.

Lastly, because performance can vary based on sample size, we also provide an estimate of performance for the most common binary, asthma, and continuous phenotype, triglycerides, for three different sample sizes (Table S2). As expected, these runs took longer and had lower R^2 than the previous runs that used the largest number of samples. Regardless of sample size, however, the PRS-CS and PRS.jl programs had nearly identical accuracies for

the traits with similar sample sizes and consistent runtime improvements with PRS.jl.

Discussion

PRSs are hailed for their potential to revolutionize clinical and precision medicine (Torkamani et al, 2018; Reay et al, 2020). Despite early successes there remain considerable concerns relating to the broader applicability of PRSs to genetically diverse populations and the computational power required to use these approaches at scale. With the growing availability of large-scale biobanks including All of Us (All of Us Research Program Investigators et al, 2019), Biobank Japan (Nagai et al, 2017), FinnGen (Kurki et al, 2022 Preprint), and UK Biobank (Bycroft et al, 2018), the need for improved genomic analysis tools that have the potential to handle these larger sample sets in a faster, less computationally intensive manner without sacrificing efficacy is paramount. The Julia programming language has many features that allow for these improvements including an efficient type-system and multiple dispatch, a variety of optimized matrix routines, and a straightforward application programming interface for accessing single instruction, multiple data (SIMD), and multi-threading. Specifically, the efficient type-system together with multiple dispatches means that the right version of functions can be called on in a computational manner that does not require checking types at runtime. Optimized matrix routines can also prevent excess memory usage, for instance, in the linkage disequilibrium calculation where a symmetric matrix type can be used. We utilize Julia's multi-threading capabilities to provide speedups beyond those available from using multithreading in basic linear algebra subprograms (BLAS), particularly in the MCMC implementation. Indeed, computation efficiency profiling, where we




Figure 1. Plots comparing polygenic risk score–continuous shrinkage (PRS-CS) and PRS.jl PRS estimates for each trait.

(A, B, C, D, E, F, G, H, I) Plots of the PRSs calculated by the python implementation of PRS-CS (PRS-CS.py) on the y-axis compared with the scores calculated by PRS.jl on the x-axis for each trait: (A) asthma, (B) coronary artery disease, (C) type 2 diabetes mellitus, (D) body mass index, (E) cholesterol, (F) estimated glomerular filtration rate, (G) high-density lipoprotein, (H) low-density lipoprotein, and (I) triglycerides. The correlation R^2 are presented in the corner of each plot.

estimate the memory and CPU usage in individual runs for both the original (Python) implementation and the proposed (Julia) variant, demonstrates that these multi-threading capabilities have the capacity to drive the large speedups.

On the asthma benchmark, Julia uses a maximum of ~8 GB of memory, whereas Python used a maximum of ~6 GB of memory. For triglycerides, Julia and Python use approximate maximums of 5 and 2.5 GB, respectively. This difference may also be due in part to how memory is managed in each language. Julia uses a garbage collector (GC) to manage and collect user-allocated data, whereas Python uses a mix of reference counting (Refcounting) and garbage

collection. Refcounting is a deterministic mechanism, allowing data to be freed almost exactly as soon as it can be proven to be no longer used; GC, on the other hand, more lazily (and generally stochastically) frees data, because of tradeoffs inherent to GC design. However, GC trades higher overall memory usage for generally better performance of user code. As such, the Julia code which allocates the same amount of memory as the Python code has the potential to execute more efficiently. Thus, even though Julia uses more memory for the same numerical computations, it is expected that Julia’s performance advantage over python is partially because of the usage of a GC instead of Refcounting. In

Table 2. Median squared error and P-value from the t test comparing SNP weights between python and Julia implementations for a single run.

	Median square error	P-value	SNP count	
			GWAS	Polygenic risk score
Asthma	2.07×10^{-11}	0.89	8,270,130	494,889
Body mass index	6.55×10^{-11}	1.00	2,529,253	719,311
Coronary artery disease	6.83×10^{-11}	0.91	8,440,435	782,510
eGFR	3.22×10^{-11}	0.93	17,393,472	774,105
HDL	3.29×10^{-11}	0.95	2,433,797	696,196
LDL	3.19×10^{-11}	0.97	2,424,334	695,115
Total cholesterol	3.25×10^{-11}	0.87	2,433,332	696,147
Triglycerides	3.17×10^{-11}	0.86	2,425,960	695,255
Type 2 diabetes mellitus	2.00×10^{-11}	0.85	35,369,247	780,627

eGFR, estimated glomerular filtration rate; GWAS, genome-wide association study; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SNP, single nucleotide polymorphism.

Table 3. Comparison of polygenic risk score–continuous shrinkage (PRS-CS) and PRS.jl performance for quantitative traits using, as covariates, age, sex, and PCs 1–10.

	R ²		Number of subjects
	PRS-CS	PRS.jl	
Body mass index	0.1141 (<0.0001)	0.1141 (<0.0001)	60,584
Cholesterol	0.1089 (0.0002)	0.1088 (0.0002)	34,347
eGFR	0.4921 (<0.0001)	0.4922 (<0.0001)	34,797
High-density lipoprotein	0.2326 (<0.0001)	0.2326 (<0.0001)	33,338
Low-density lipoprotein	0.0835 (<0.0001)	0.0835 (0.0001)	32,061
Triglycerides	0.0657 (<0.0001)	0.0657 (<0.0001)	34,531

All data is presented as mean (SD).

Table 4. Comparison of polygenic risk score–continuous shrinkage (PRS-CS) and PRS.jl performance for binary traits.

	Nagelkerke R ²		Area under the curve		10% odds ratio		Number of subjects	
	PRS-CS	PRS.jl	PRS-CS	PRS.jl	PRS-CS	PRS.jl	Cases	Controls
Asthma	0.0176 (<0.0001)	0.0176 (<0.0001)	0.560 (<0.0001)	0.560 (0.0002)	1.54 (0.02)	1.54 (0.02)	8,210	64,618
Coronary artery disease	0.3212 (0.0001)	0.3214 (0.0001)	0.552 (0.0004)	0.552 (0.0005)	1.71 (0.02)	1.73 (0.01)	16,807	56,021
Type 2 diabetes mellitus	0.1715 (<0.0001)	0.1716 (<0.0001)	0.626 (0.0001)	0.626 (0.0001)	2.75 (0.017)	2.77 (0.008)	13,688	59,140

All data is presented as mean (SD).

additional, Julia's GC uses heuristics based on total available system memory to determine when to pause execution and initiate expensive GC scans; therefore, maximum memory usage measurements are not reliable predictors of memory requirements and will vary based on the amount of memory available on the system being used.

On the benchmark for average CPU usage, of the theoretical 800% usage possible with eight cores, Julia averages ~700%, whereas Python averages only about 300%. Both PRS.jl and PRS-CS use the same multi-threaded BLAS (openBLAS) to efficiently execute BLAS operations. Without additional speedups, PRS.jl would likely achieve only similar performance. However, PRS.jl uses

additional multi-threaded mechanisms to achieve further speedups. Part of those speedups come from CSV reading (implemented in the CSV.jl package), although those improvements are limited to the relatively short CSV parsing phase. Most of the speedup is expected to come from multi-threading of the MCMC algorithm, which has many parallelizable regions of calculations. Specifically, updates of many model parameters are all executed with multi-threading, minimizing the span of non-scaling single-threaded regions of the execution.

Here, we demonstrate how a basic port of the commonly used PRS-CS package to the Julia language, PRS.jl, can improve the program's speed without sacrificing PRS accuracy across a variety of

traits. PRS.jl is freely available for download through GitHub (github.com/fauconab/PolygenicRiskScores.jl) and is a drop-in replacement for PRS-CS. Small usability improvements were made that allow the user to supply summary statistics with columns in any order and allows the user to specify supplied column names. No major changes to the algorithm code were made. Thus, the improvements reflect advantages of the Julia programming language over Python.

The available README text instructs even novice Julia programming language users how to execute this software with ease. Because of the usability and performance improvements, we believe PRS.jl will allow for broader and more efficient use of PRSs in genomic medicine.

Furthermore, the development of tools for genomic analyses that are both fast and computationally efficient, such as PRS.jl, have the potential to democratize genomic research. To date, human genomics research is overrepresented by high-income countries, which tend to have more powerful computational resources and greater funding for the sciences. The lack of population diversity and global representation is driven by many factors; however, a lack of resources, financial and human, are consistently noted as key limitations that prevent middle- and low-income countries from fully using and contributing to genomic research (Marques-de-Faria et al, 2004; Hardy et al, 2008; Seguin et al, 2008; Kaur et al, 2019). Because of this disparity, these countries could benefit the most from advances in genomic medicine.

Knowing the impact, utility, and potential of PRSs to drive personalized medicine while acknowledging the immense bias in data availability and usage, the National Institutes of Health funded a large initiative to fund PRS research in diverse populations. By reducing the computational needs of key algorithms, low resourced research groups can use these algorithms to benefit their scientific endeavors and provide potential benefit for their populations. The current versions of PRS-CS and PRS.jl are limited in their utility in ancestrally diverse populations (Duncan et al, 2019), a limitation that has been addressed by PRS-CSx (Ruan et al, 2022). Future work to extend Julia improvements to the PRS-CSx framework for faster trans-ancestry PRS calculations has been planned.

The PRSs in this set of work are derived using standard inputs and publicly available summary statistics. Different discovery GWASs for the same traits can provide different polygenic risk estimates at the individual level (Schultz et al, 2022); therefore, association of scores to clinical values in this paper may be different than other papers using similar clinical traits because of differences in the discovery summary statistics. As such, the PRSs generated in this paper do not represent the most optimized PRS for any particular trait. Despite this limitation in study design, our work clearly demonstrates that the accuracy for both the Python and Julia versions of PRS-CS are nearly identical. Because the base datasets and testing populations are identical, our design allows for a head-to-head comparison of PRS-CS versus PRS.jl. Additional study limitations include the usage of a direct translation of the PRS-CS package. Although this approach allows us to directly compare the accuracy performance across the Python and Julia implementations, it does not fully use the various computational improvements that Julia affords. For example, future work aims to

use Julia's multi-threading and GPU compute capabilities and are effective methods for computational acceleration of programs which heavily use matrix operations. These additional compute capabilities would allow PRS.jl to better use the hardware that users have available and make processing of even larger datasets feasible.

Materials and Methods

PRS.jl development

PRS-CS was cloned from <https://github.com/getian107/PRScs>. This implementation was translated to the Julia programming language. Development of PRS.jl was carried out in the open, with all contributions being publicly posted to the PRS.jl GitHub repository.

Training dataset and example phenotypes

We used the Vanderbilt University Medical Center Synthetic Derivative (VUMC SD), a deidentified copy of the electronic health record (EHR), for the identification of the nine test phenotypes. VUMC is a tertiary care center that provides inpatient and outpatient care in Nashville, TN. The SD includes more than 2.8 million patient records that contain International Classification of Diseases, 9th and 10th editions (ICD-9 and ICD-10), codes; Current Procedural Terminology codes; laboratory values; medication usage; and clinical documentation (Rodén et al, 2008). From the SD, a subset of patients are part of VUMC BioVU, a biobank that links the deidentified EHRs of patients to discarded blood samples for the extraction of genetic materials (Rodén et al, 2008). The VUMC Institutional Review Board oversees BioVU and approved these projects.

Genotyping and quality control

We obtained genome-wide data from 94,474 BioVU individuals genotyped on the Illumina MEGA^{EX} array. We used PLINK v1.9 to filter genotypes with low SNP (<0.95) call rate and individuals with low call rate (<0.98), sex discrepancies, and excessive heterozygosity ($|F_{het}| > 0.2$). Principal component analysis on the genotyped BioVU cohort together with CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), YRI (Yoruba in Ibadan, Nigeria), and CHB (Han Chinese in Beijing, China) individuals from the 1000 Genomes Project Consortium et al (2015) from the CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), YRI (Yoruba in Ibadan, Nigeria), and CHB (Han Chinese in Beijing, China) populations were used to create the CEU-YRI and CEU-CHB axes in FlashPCA2. Simple thresholding was used (0.3 and greater on the CEU-YRI axis and 0.4 and greater on the CEU-CHB axis) to select individuals of recent European ancestry as shown in Fig S1.

We confirmed the absence of genotyping batch effects through logistic regression with “batch” as the phenotype. We used the Michigan Imputation Server (Das et al, 2016) with the reference panel from the Haplotype Reference Consortium to impute

genotypes. SNPs were filtered for imputation quality ($R^2 > 0.3$ or $INFO > 0.95$) and converted to hard calls. We restricted PRS calculations to autosomal SNPs with minor allele frequency above 0.01. We removed SNPs that differed by more than 10% in minor allele frequency from the 1000 Genomes Project phase 3 CEU (1000 Genomes Project Consortium et al, 2015) set and those with a Hardy–Weinberg equilibrium $P < 10^{-10}$. The resulting data set contained hard-called SNP information for 9,386,383 SNPs in 72,828 individuals of European ancestry.

PRS calculations

We calculate PRSs for individuals using PRS-CS (Ge et al, 2019) and our translation of the package to the Julia programming language, PRS.jl. PRS-CS/PRS.jl uses Bayesian regression with a CS before model polygenic effects on the phenotype and updates the weight of each SNP within each LD block in posterior inference. The program can use an assigned global shrinkage parameter or automatically learn the parameter from the data.

Model performance in BioVU

Summary statistics were downloaded for six quantitative traits: body mass index, high-density lipid cholesterol, low-density lipid cholesterol, total cholesterol, triglycerides, and estimated glomerular filtration rate (Willer et al, 2013; Hellwege et al, 2019; Pulit et al, 2019) and three binary traits: asthma, coronary artery disease, and type 2 diabetes mellitus (T2DM) (Preuss et al, 2010; Zhu et al, 2019; Vujkovic et al, 2020). These traits were chosen because of their high prevalence or phenotypic validation in the VUMC EHR and usage in the original PRS-CS manuscript.

Summary statistics were processed to get these input files in a format that the original PRS-CS method can accept (columns reordered and renamed using R). PRSs were calculated in triplicate using a single-CPU architecture. Furthermore, to demonstrate the task-dependent performance improvements based on sample size, we also estimated the PRS performance for three sample sizes, 72,828 for the total population and two random subsets of the totally sized 36,000 and 18,000 individuals. Because the final sample size used in the estimate is based on the number of patients in the set with the particular outcome, we chose the most prevalent binary and continuous outcomes for this step.

The scripts used to call both programs are available at <https://juliahub.com/ui/Packages/PolygenicRiskScores/zm2vm/0.1.0>.

Computational performance comparison

All computations were performed using the Vanderbilt University's Advanced Computing Center for Research and Education (ACCRES, www.accres.vanderbilt.edu). Each PRS run was restricted to a single Haswell node with an allocation of eight CPUs and 80 GB of memory. To minimize runtime variabilities related to cluster usage, we initiated the PRS-CS and PRS.jl runs for each phenotype simultaneously. Subsequent benchmarking runs were initiated over a 3-month time course. The processing time for each PRS run was recorded. The mean and SD of the three runs per phenotype were calculated.

PRS.jl and PRS.py performance comparison

The PRS-CS method uses a global shrinkage parameter to account for varying trait polygenicity. If a trait is highly polygenic, the global shrinkage parameter tends to be larger, whereas if the trait is less polygenic, the global shrinkage parameter will be smaller. PRS.jl and PRS-CS have two options, one of which allows the global shrinkage parameter to be automatically learned from the data rather than supplied, auto (ϕ). Sensitivity analyses demonstrated similar output for the two methods when using a fixed global shrinkage parameter or the auto algorithm. Thus, in each case, we used the auto version, allowing for the estimation of the global shrinkage parameter from the data. Once the posterior β values were calculated, PLINK v1.9 was used to score each individual. PRSs for each phenotype were scaled to have mean zero and unit SD using the built-in R `scale()` function. Prediction accuracy was assessed using real phenotypic values in BioVU and covariate adjustment (sex, age, and PCs 1–10).

Verification of quantitative trait performance in BioVU

Accuracy of PRSs calculated from quantitative trait summary statistics was assessed using ordinary least squares R^2 between the scaled PRSs, and median values by person from BioVU data processed by a previously published quality control pipeline called Quality Lab (Dennis et al, 2021).

Verification of binary trait performance in BioVU

Because R^2 cannot be used for binary logistic regression, accuracy of PRSs trained from binary trait summary statistics was assessed using three measures commonly used in the PRS literature: the AUC, the Nagelkerke Pseudo R^2 , and the odds ratio of the top 10% compared against the bottom 90% between the scaled PRSs and the binary presence of clinical codes that are representative of the clinical disease. The AUC, or area under the receiver operating characteristic curve, provides an aggregate measure that is valuable because it measures how well predictions are ranked irrespective of classification threshold. The Nagelkerke Pseudo R^2 is an analog of the ordinary least squares R^2 for logistic regression and is a commonly used to describe how well the PRS explains a binary trait (Choi et al, 2020; Maj et al, 2022). The odds ratio of the top 10% compared against the bottom 90% is a common metric used to describe how well a PRS captures the risk of developing the disease and has been used to demonstrate the validity and clinical relevance of PRSs (Khera et al, 2018). The specific codes used for asthma and coronary artery disease are available in Table S3. These codes include ICD-9 and -10 codes that mirror the clinical disease. For type 2 diabetes mellitus, however, the presence of the condition was determined using an updated version of a previously published phenotyping algorithm which is effective at distinguishing type 1 and type 2 diabetes (Pacheco & Thompson, 2012).

Data Availability

GWAS summary statistics were downloaded from publicly available resources. BioVU summary statistics are made available upon

reasonable request to authors. PRS-CS/PRS.jl is available for download from GitHub (<https://github.com/fauconab/PolygenicRiskScores.jl>).

Supplementary Information

Supplementary information is available at <https://doi.org/10.26508/lsa.202201382>.

Acknowledgments

The work was supported by the following National Institutes of Health grants: 2R01CA157823-07A1, R01HL151152, U01HG011720, and P50MD017347. The dataset used for performance characterization was obtained from the Vanderbilt University Medical Center Synthetic Derivative, which is supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by the Clinical and Translational Science Awards (CTSA) grant UL1TR000445 from National Center for Advancing Translational Sciences/ National Institutes of Health.

Author Contributions

A Faucon: conceptualization, resources, data curation, software, formal analysis, validation, investigation, visualization, and writing—original draft, review, and editing.

J Samaroo: conceptualization, resources, data curation, software, formal analysis, validation, investigation, methodology, and writing—review and editing.

T Ge: resources, methodology, and writing—review and editing.

LK Davis: resources, data curation, supervision, funding acquisition, and writing—review and editing.

NJ Cox: conceptualization, resources, data curation, supervision, funding acquisition, and writing—original draft, review, and editing.

R Tao: resources, investigation, methodology, and writing—review and editing.

MM Shuey: conceptualization, resources, data curation, software, formal analysis, supervision, investigation, visualization, methodology, project administration, and writing—original draft, review, and editing.

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

References

- 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, et al (2015) A global reference for human genetic variation. *Nature* 526: 68–74. doi:10.1038/nature15393
- Bezanson J, Chen J, Chung B, Karpinski S, Shah VB, Vitek J, Zoubritzky L (2018) Julia: Dynamism and performance reconciled by design. *Proc ACM Program Lang* 2: 1–23. doi:10.1145/3276490
- Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, et al (2018) The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562: 203–209. doi:10.1038/s41586-018-0579-z

- Chatterjee N, Shi J, Garcia-Closas M (2016) Developing and evaluating polygenic risk prediction models for stratified disease prevention. *Nat Rev Genet* 17: 392–406. doi:10.1038/nrg.2016.27
- Choi SW, Mak TSH, O'Reilly PF (2020) Tutorial: A guide to performing polygenic risk score analyses. *Nat Protoc* 15: 2759–2772. doi:10.1038/s41596-020-0353-1
- Choi SW, O'Reilly PF (2019) PRSice-2: Polygenic risk score software for biobank-scale data. *Gigascience* 8: giz082. doi:10.1093/gigascience/giz082
- Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy S, McGue M, et al (2016) Next-generation genotype imputation service and methods. *Nat Genet* 48: 1284–1287. doi:10.1038/ng.3656
- Dennis JK, Sealock JM, Straub P, Lee YH, Hucks D, Actkins K, Faucon A, Feng YCA, Ge T, Goleva SB, et al (2021) Clinical laboratory test-wide association scan of polygenic scores identifies biomarkers of complex disease. *Genome Med* 13: 6. doi:10.1186/s13073-020-00820-8
- All of Us Research Program Investigators, Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, Dishman E, (2019) The “all of us” research program. *N Engl J Med* 381: 668–676. doi:10.1056/nejmsr1809937
- Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, Peterson R, Domingue B (2019) Analysis of polygenic risk score usage and performance in diverse human populations. *Nat Commun* 10: 3328. doi:10.1038/s41467-019-11112-0
- Falconer DS (1965) The inheritance of liability to certain diseases, estimated from the incidence among relatives. *Ann Hum Genet* 29: 51–76. doi:10.1111/j.1469-1809.1965.tb00500.x
- Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW (2019) Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun* 10: 1776. doi:10.1038/s41467-019-09718-5
- Hardy BJ, Seguin B, Goodsaid F, Jimenez-Sanchez G, Singer PA, Daar AS (2008) The next steps for genomic medicine: Challenges and opportunities for the developing world. *Nat Rev Genet* 9: S23–S27. doi:10.1038/nrg2444
- Hellwege JN, Velez Edwards DR, Giri A, Qiu C, Park J, Torstenson ES, Keaton JM, Wilson OD, Robinson-Cohen C, Chung CP, et al (2019) Mapping eGFR loci to the renal transcriptome and phenotype in the VA Million Veteran Program. *Nat Commun* 10: 3842. doi:10.1038/s41467-019-11704-w
- Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, Chan AT, Chang-Claude J, Du M, Gong J, et al (2015) A model to determine colorectal cancer risk using common genetic susceptibility loci. *Gastroenterology* 148: 1330–1339.e14. doi:10.1053/j.gastro.2015.02.010
- Kaur M, Hadley DW, Muenke M, Hart PS (2019) An international summit in human genetics and genomics: Empowering clinical practice and research in developing countries. *Mol Genet Genomic Med* 7: e00599. doi:10.1002/mgg3.599
- Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, et al (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet* 50: 1219–1224. doi:10.1038/s41588-018-0183-z
- Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, et al (2022) FinnGen: Unique genetic insights from combining isolated population and national health register data. *medRxiv*. doi:10.1101/2022.03.03.22271360 (Preprint posted March 6, 2022)
- Langmead B, Nellore A (2018) Cloud computing for genomic data analysis and collaboration. *Nat Rev Genet* 19: 325. doi:10.1038/nrg.2018.8
- Maj C, Salvi E, Citterio L, Borisov O, Simonini M, Glorioso V, Barlassina C, Glorioso N, Thijs L, Kuznetsova T, et al (2022) Dissecting the polygenic

- basis of primary hypertension: Identification of key pathway-specific components. *Front Cardiovasc Med* 9: 814502. doi:10.3389/fcvm.2022.814502
- Marques-de-Faria AP, Ferraz VEF, Acosta AX, Brunoni D (2004) Clinical genetics in developing countries: The case of Brazil. *Community Genet* 7: 95–105. doi:10.1159/000080777
- Mega JL, Stitzel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, et al (2015) Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials. *Lancet* 385: 2264–2271. doi:10.1016/s0140-6736(14)61730-x
- Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Mushiroda T, et al (2017) Overview of the BioBank Japan project: Study design and profile. *J Epidemiol* 27: S2–S8. doi:10.1016/j.je.2016.12.005
- Pacheco J, Thompson W (2012) Type 2 diabetes mellitus. PheKB. Available from: <https://phekb.org/phenotype/18>.
- Pain O, Glanville KP, Hagenaars SP, Selzam S, Furtjes AE, Gaspar HA, Coleman JRI, Rinfeld K, Breen G, Plomin R, et al (2021) Evaluation of polygenic prediction methodology within a reference-standardized framework. *PLoS Genet* 17: e1009021. doi:10.1371/journal.pgen.1009021
- Preuss M, König IR, Thompson JR, Erdmann J, Absher D, Assimes TL, Blankenberg S, Boerwinkle E, Chen L, Cupples LA, et al (2010) Design of the coronary ARtery Disease genome-wide replication and meta-analysis (CARDIoGRAM) study: A genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. *Circ Cardiovasc Genet* 3: 475–483. doi:10.1161/circgenetics.109.899443
- Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, Yengo L, Ferreira T, Marouli E, Ji Y, et al (2019) Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* 28: 166–174. doi:10.1093/hmg/ddy327
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81: 559–575. doi:10.1086/519795
- Reay WR, Atkins JR, Carr VJ, Green MJ, Cairns MJ (2020) Pharmacological enrichment of polygenic risk for precision medicine in complex disorders. *Sci Rep* 10: 879. doi:10.1038/s41598-020-57795-0
- Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balsler JR, Masys DR (2008) Development of a large-scale de-identified DNA biobank to enable personalized medicine. *Clin Pharmacol Ther* 84: 362–369. doi:10.1038/clpt.2008.89
- Ruan Y, Lin YF, Feng YCA, Chen CY, Lam M, Guo Z, Stanley Global Asia Initiatives, He L, Sawa A, Martin AR, et al (2022) Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* 54: 573–580. doi:10.1038/s41588-022-01054-7
- Schultz LM, Merikangas AK, Ruparel K, Jacquemont S, Glahn DC, Gur RE, Barzilay R, Almasy L (2022) Stability of polygenic scores across discovery genome-wide association studies. *HGG Adv* 3: 100091. doi:10.1016/j.xhgg.2022.100091
- Seguin B, Hardy BJ, Singer PA, Daar AS (2008) Genomic medicine and developing countries: Creating a room of their own. *Nat Rev Genet* 9: 487–493. doi:10.1038/nrg2379
- Speed D, Balding DJ (2014) MultiBLUP: Improved SNP-based prediction for complex traits. *Genome Res* 24: 1550–1557. doi:10.1101/gr.169375.113
- Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S (2013) Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. *Arterioscler Thromb Vasc Biol* 33: 2261–2266. doi:10.1161/atvbaha.112.301120
- Torkamani A, Wineinger NE, Topol EJ (2018) The personal and clinical utility of polygenic risk scores. *Nat Rev Genet* 19: 581–590. doi:10.1038/s41576-018-0018-x
- Vilhjalmsson BJ, Yang J, Finucane HK, Gusev A, Lindstrom S, Ripke S, Genovese G, Loh PR, Bhatia G, Do R, et al (2015) Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am J Hum Genet* 97: 576–592. doi:10.1016/j.ajhg.2015.09.001
- Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, Huffman JE, Assimes TL, Lorenz K, Zhu X, et al (2020) Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet* 52: 680–691. doi:10.1038/s41588-020-0637-y
- Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, et al (2013) Discovery and refinement of loci associated with lipid levels. *Nat Genet* 45: 1274–1283. doi:10.1038/ng.2797
- Zhu Z, Zhu X, Liu CL, Shi H, Shen S, Yang Y, Hasegawa K, Camargo CA, Jr., Liang L (2019) Shared genetics of asthma and mental health disorders: A large-scale genome-wide cross-trait analysis. *Eur Respir J* 54: 1901507. doi:10.1183/13993003.01507-2019



License: This article is available under a Creative Commons License (Attribution 4.0 International, as described at <https://creativecommons.org/licenses/by/4.0/>).